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Abstract
AIM: To evaluate the effect of antiviral agents on 
intrahepatic HBV DNA in HBeAg-positive chronic hepatitis 
B patients. 
METHODS: Seventy-one patients received treatment 
with lamivudine, interferon alpha (IFN-α2b) or sequential 
therapy with lamivudine-IFN-α2b for 48 wk. All subjects 
were followed up for 24 wk. Serum and intrahepatic 
HBV DNA were measured quantitatively by PCR. HBV 
genotypes were analyzed by PCR-RFLP.
RESULTS: At the end of treatment, the intrahepatic 
HBV DNA level in 71 patients decreased from a mean of 
(6.1 ± 1.0) log10 to (4.9 ± 1.4) log10. Further, a larger 
decrease was seen in the intrahepatic HBV DNA level 
in patients with HBeAg seroconversion. Intrahepatic 
HBV DNA level (before and after treatment) was not 
significantly affected by the patients’ HBV genotype, or 
by the probability of virological flare after treatment. 
CONCLUSION: Intrahepatic HBV DNA can be effectively 
lowered by antiviral agents and is a significant marker 
for monitoring antivirus treatment. Low intrahepatic 
HBV DNA level may achieve better efficacy of antivirus 
treatment. 
© 2007 The WJG Press. All rights reserved.
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INTRODUCTION
Hepatitis B virus (HBV) is one of  the major causes of  
liver disease worldwide. Approximately more than 350 
million people in the world are chronic carriers, and 
eventually 15%-25% of  them could progress to end-stage 
liver disease and hepatocellular carcinoma, ranking ninth 
globally among all causes of  mortality (up to 1 million 
deaths annually)[1]. Fortunately, several therapies have 
been developed for chronic hepatitis B. Anti-viral therapy 
is believed to be the most important strategy. Currently 
available anti-viral drugs include interferon-alpha[2-4] 
and nucleoside analogue agents[5-9]. It was reported that 
long-term anti-viral treatment can improve fibrosis and 
cirrhosis, increase survival rate and decrease the incidence 
of  hepatocellular carcinoma in patients with chronic 
hepatitis B[10,11]. Nonetheless, when the treatment with anti-
viral drugs is stopped, relapse occurs in a great majority of  
patients, even if  they have undetectable serum HBV DNA, 
normal serum alanine aminotransferase level and HBeAg 
seroconversion. 
Therefore, it is important to determine which end 
points should be used to judge the success or failure of  
treatment and assist in determining how long therapy 
should be maintained. Since biopsy specimens from 
chronic HBV patients are not easy to obtain, intrahepatic 
HBV DNA level is not often studied. The aim of  the 
present study was to analyze the effect of  anti-viral drugs 
on intrahepatic HBV DNA and the relationship between 
intrahepatic HBV DNA and the long-term efficacy of  
antivirus treatment.
MATERIALS AND METHODS
Subjects
Between March 2003 and March 2005, 71 patients (59 
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males and 12 females) with HBeAg-positive chronic 
hepatitis B were recruited. Their age was 19-47 (mean 
32 ± 9) years. Informed consent was obtained from 
all patients. The patients were matched according to 
the following criteria: positive for HBsAg and HBeAg, 
serum HBV DNA ≥ 1 × 105 copies/L, serum alanine 
aminotransferase (ALT) level above at least two-fold the 
normal range (normal range 0-667 nkat/L) for more 
than 6 mo. Exclusion criteria were as follows: alcoholism, 
pregnancy, cirrhosis, chronic renal failure, concurrent 
autoimmune disease, serious neurological disorders, 
human immunodeficiency virus (HIV) infection and viral 
hepatitis A, C, delta or E. Patients treated with interferon 
or other anti-viral therapies for 6 mo prior to enrollment 
in this study were also excluded. Patients were treated with 
100 mg oral lamivudine daily (n = 35), or lamivudine 
during the first 8 mo and IFN-α from mo 7 to 12 (n = 24) 
or 5 million units of  interferon-alpha (IFN-α), three times 
per week (n = 12). Treatment groups were randomized at 
the ratio 3:2:1. The total duration of  therapy was 12 mo. 
All subjects were followed up for 24 wk after the 12 mo of  
treatment. Presence of  serum HBV DNA level ≤ 1 × 103 
and normalization of  serum ALT level were assessed as 
treatment response.
Measurement of hepatitis B virus markers and biochemical 
tests 
Blood samples were obtained before and after treatment 
and at the 24 wk follow-up visit. Liver biochemistry and 
HBV marker test (enzyme-linked immunosorbant assay) 
were performed on these samples. 
Liver biopsy specimens were collected by needle 
biopsies (0.5 cm-1.5 cm) before and after treatment. The 
tissue was washed several times in cold phosphate buffered 
saline (PBS) and stored at -70℃. Total DNA was extracted 
from liver tissue with Qiaamp DNA tissue Mini DNA kit 
(Qiagen, Germany). Serum and intrahepatic HBV DNA 
were measured quantitatively by real-time polymerase chain 
reaction (PCR) (Model 5700, ABI Company, USA) with a 
lower limit of  detection of  1 × 103 HBV DNA copies/L and 
1 × 103 copies/g total DNA, respectively. HBV genotypes 
were determined by PCR restriction fragment length 
polymorphism (PCR-RFLP) analysis[12].
Detection of histological inflammatory score
Histological inflammatory score was detected with the 
Knodell scoring system. Histological response was defined 
as a decrease by at least two points in the Knodell scoring 
system[13]. 
Statistical analysis
Data were analyzed with the Statistical Program for Social 
Sciences (SPSS 13.0 for Windows). Categorical variables 
were tested using chi-square test or Fisher’s exact test. 
Normally distributed variables were tested using t-test 
or ANOVA, whereas continuous variables with skewed 
distribution were tested using the Kruskal Wallis test. A 
regression model was used for univariate and multivariate 
analysis. P < 0.05 was considered statistically significant.
RESULTS
Histological, biochemical and virological data 
At the end of  treatment, the mean values of  Knodell 
score, serum HBV DNA level, intrahepatic HBV DNA 
level, and serum ALT level in all the 71 patients declined 
significantly (P < 0.05). HBeAg seroconversion occurred 
in 17 out of  the 71 patients. There was no significant 
difference in above mentioned parameters between HBeAg 
seroconversion group and HBeAg positive group before 
treatment (P > 0.05), except for the baseline intrahepatic 
HBV DNA levels (5.6 ± 1.2) log10 and (6.3 ± 0.8 ) 
log10, respectively (P = 0.02). After treatment, HBeAg 
seroconversion group had better improvement than 
HBeAg positive group. The mean intrahepatic HBV DNA 
decreased to (4.1 ± 0.8) log10 in seroconversion group (P 
= 0.0124), and to (5.1 ± 1.5) log10 (P = 0.0872) in HBeAg 
positive group (Table 1).
Intrahepatic HBV DNA level and HBV genotype
At the end of  treatment, the intrahepatic HBV DNA 
load was less than 5 log10 in 38 patients, and higher than 
5 log10 in 33 patients (P < 0.05). The difference was 
not statistically significant in serum HBV DNA load, 
histology and serum ALT level before treatment. After 
treatment, compared with the patients with intrahepatic 
HBV DNA load greater than 5 log10, greater reduction 
in above mentioned parameters was seen in patients with 
intrahepatic HBV DNA load less than 5 log10. After 
24 wk of  treatment, sustained virological response rate 
and ALT normalization rate were very similar between two 
groups (P > 0.05) (Table 2). Regression analysis showed 
that virological flares after antiviral treatment were not 
correlated with the baseline or post-treatment level of  
Table 1  Histological and virological characteristics of 71 patients with chronic HBV infection  mean ± SD
Parameter Total (n = 71) HBeAg positive (n = 54) HBeAg seroconversion (n = 17)
Knodell score: pretreatment    8.2 ± 4.1         8.4 ± 4.1               7.1 ± 4.2 
                          post-treatment     5.8 ± 3.4a         6.0 ± 3.6               5.1 ± 3.1a
Intrahepatic HBV DNA (log10): pretreatment    6.1 ± 1.0         6.3 ± 0.8               5.6 ± 1.2
                                                         post-treatment    4.9 ± 1.4a         5.1 ± 1.5               4.1 ± 0.8a
Serum HBV DNA (log10): pretreatment      7.7 ± 1.1         7.9 ± 0.9               7.5 ± 1.0
                                               post-treatment     4.0 ± 1.3a         4.4 ± 1.4a               3.0 ± 0.2a
ALT (nkat/L): pretreatmen 3390 ± 2321      3206 ± 2354            3841 ± 2371
                          post-treatment                  868 ± 885a      9853 ± 985              618 ± 659a
aP < 0.05 vs pretreatment.
intrahepatic HBV DNA load (P > 0.05). 
HBV genotype C accounted for 85.9% (n = 61), and 
genotype B for 14.1% (n = 10). The mean intrahepatic 
HBV DNA loads in genotype C patients before and after 
treatment were (6.1 ± 0.9) log10 and (4.9 ± 1.4) log10 
(P < 0.05), and (5.6 ± 1.5) log10 and (4.7 ± 1.2) log10 in 
genotype B patients, respectively (P > 0.05). There was 
no statistically significant difference in serum intrahepatic 
HBV DNA load and ALT level between the two groups 
at the end of  treatment and in any of  the parameters 
measured after 24 wk of  treatment (P > 0.05). After 24 wk 
of  treatment, sustained virological response rate and ALT 
normalization rate were similar (Table 2).
Antiviral outcome 
There was no significant difference in all the parameters 
among the three groups before treatment (P > 0.05). At 
the end of  treatment, the antiviral effect of  sequential 
lamivudine-INF-α therapy and lamivudine monotherapy 
was similar (P > 0.05), which was superior to that of  
INF-α monotherapy (P < 0.05). Reduction of  intrahepatic 
HBV DNA was greater in lamivudine-INF-α therapy 
group and lamivudine monotherapy group than in INF-α 
monotherapy group, suggesting that the nucleoside 
analogue agents might play a stronger role than INF-α in 
inhibiting intrahepatic HBV DNA (data not shown). 
DISCUSSION
Due to recent advancements, chronic hepatitis B has 
become a treatable disease. The short-term efficacy 
of  IFN-α is about 40%-60%[12,17]. Peginterferon-alpha 
(PEG IFN-α) is more effective against HBeAg-positive 
chronic hepatitis B than either lamivudine or standard 
IFN-α monotherapy[3,4]. Nucleoside analogue agents 
markedly suppress HBV DNA polymerase, and have 
numerous advantages, such as minimal side effects, ease 
of  administration. Furthermore, they show good effects 
on chronic hepatitis B, liver decompensation, cirrhosis, or 
other coexisting conditions. It was reported that serum 
HBV DNA is undectable in 80% of  patients, HBeAg 
is eliminated in 20%-25% of  them, and 60% ALT level 
becomes normal in 60% of  them after treatment with 
lamivudine[14-16]. 
Nonetheless, the efficacy of  antiviral treatment is far 
from perfect. IFN-α can achieve a sustained response 
after one year in only 20%-30% of  chronic HBV infection 
patients[17]. Relapse occurs in the majority of  patients after 
therapy. The main reason is that HBV covalently closed 
circular DNA (cccDNA) in infected hepatocytes cannot be 
eliminated by antiviral agents, leading to rebound of  HBV 
DNA after antiviral therapy[18]. The life cycle of  HBV 
relies on a covalently closed circular form of  the viral 
genome, which provides the template for viral pregenomic 
messenger RNA. Replication of  cccDNA is not semi-
conservative, and needs viral DNA cycling back to the 
nuclei to amplify and maintain the pool of  cccDNA[19,20]. 
It was reported that intrahepatic HBV cccDNA correlates 
positively with the total intrahepatic HBV DNA[21], 
suggesting that intrahepatic HBV DNA should be 
eliminated first in order to clear HBV cccDNA and 
intrahepatic HBV DNA level can be taken as a reasonable 
parameter in evaluating the efficacy of  antiviral therapy, 
thus helping decide the duration of  therapy.
The results of  our study show that antiviral treatment 
decreased the serum and intrahepatic HBV DNA as 
well as alanine aminotransferase levels in 71 patients (P 
< 0.05). HBeAg seroconversion occurred in 17 out of  
the 71 patients at the end of  treatment. There was no 
significant difference in the baseline levels of  Knodell 
score, serum ALT and HBV DNA levels between HBeAg 
seroconversion and HBeAg positive groups (P > 0.05). 
Only the intrahepatic HBV DNA level was obviously lower 
in HBeAg seroconversion group than in HBeAg positive 
group (P = 0.02). After treatment, greater improvement 
in above mentioned parameters was seen in patients with 
HBeAg seroconversion than in HBeAg positive patients. 
The mean intrahepatic HBV DNA level was lower in the 
HBeAg seroconversion group than in the HBeAg positive 
group (P = 0.010), suggesting that intrahepatic HBV DNA 
can be effectively lowered by antiviral agents and a lower 
intrahepatic HBV DNA level is able to predict the efficacy 
of  antiviral therapy. 
At the end of  treatment, the intrahepatic HBV DNA 
load was less than 5 log10 in 38 patients and greater than 
5 log10 in 33 patients. The mean intrahepatic HBV DNA 
Table 2  Intrahepatic HBV DNA level in chronic HBV patients and HBV genotypes  mean ± SD
Parameter Intrahepatic HBV DNA
< 5 log10 (n  = 38)
Intrahepatic HBV DNA
≥ 5 log10 (n  = 33)
                              HBV genotypes
Genotype C group (n  = 61)  Genotype B (n = 10)
Knodell score: pretreatment          7.6 ± 4.0          8.2 ± 4.1            8.1 ± 4.1                5.7 ± 3.2
                          post-treatment          4.8 ± 2.2a          7.4 ± 4.1            6.0 ± 3.4a                5.4 ± 3.1
Intrahepatic HBV DNA (log10): pretreatment          5.8 ± 1.0          6.3 ± 0.9            6.1 ± 0.9                5.6 ± 1.5
                                                         post-treatment          3.8 ± 0.9a          6.1 ± 0.7            4.9 ± 1.4a                4.7 ± 1.2
Serum HBV DNA (log10): pretreatment          7.6 ± 1.0          7.8 ± 1.3            7.7 ± 1.2                7.6 ± 0.8
                                               post-treatment          3.3 ± 0.7a          4.7 ± 1.4a          4.05 ± 1.3a                4.9 ± 1.2a 
Off- treatment 24 wk          5.1 ± 1.4          5.2 ± 1.7            5.1 ± 1.6                4.3 ± 1.3
ALT (nkat/L): pretreatment       4342 ± 2788       2571 ± 1519         3390 ± 2438             4509 ± 2338
                          post-treatment          634 ± 567a       1135 ± 1052           912 ± 918a               551 ± 236a 
Off-treatment 24 wk       1519 ± 1519       1637 ± 1369         1503 ± 1336             1987 ± 1720
Off-treatment 24 wk virological response rate       23.7% (9/38)       27.3% (9/33)         31.1% (19/51)             30% (3/10)
Off-treatment 24 wk ALT normalization rate       16.7% (15/38)       13.3% (10/33)         39.3% (24/51)             30% (3/10)
aP < 0.05 vs pretreatment.
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load before and after treatment was obviously lower in 
the patients with intrahepatic HBV DNA load less than 
5 log10 than in the patients with intrahepatic HBV DNA 
load greater than 5 log10 (P < 0.05), and the difference 
was not statistically significant in the other parameters. At 
the end of  treatment, greater reduction in the measured 
parameters was seen in patients with intrahepatic HBV 
DNA load less than 5 log10, indicating that reduction in 
intrahepatic HBV DNA load is also very important in 
antiviral treatment. After 24 wk of  treatment, sustained 
virus response rate and ALT normalization rate for the 
two groups were very similar (23.7% and 16.7%, 27.3% 
and 13.3%, respectively, P > 0.05). Regression analysis 
showed that virus flares after antiviral treatment were not 
correlated with the baseline or with the post-treatment 
level of  serum and intrahepatic HBV DNA load (r < 0.05, 
P > 0.05). A possible reason is that the duration of  antiviral 
treatment in this study was too short to eliminate or largely 
lessen the intrahepatic HBV DNA load. Therefore, once 
the antiviral drugs are withdrawn, the majority of  patients 
would experience virus rebound. Intrahepatic HBV DNA 
was undetectable even if  the patients had undetectable 
serum HBV DNA, indicating that intrahepatic HBV DNA 
is more useful than serum HBV DNA in monitoring the 
efficacy of  antivirus therapy, and loss of  intrahepatic HBV 
DNA might be crucial for the patients to achieve sustained 
antiviral response.
HBV is classified into 8 genotypes (A-H), each showing 
a distinct geographical distribution and disease progression. 
HBV genotype C is believed to be associated with a 
higher risk of  reactivation and progression to cirrhosis 
compared to HBV genotype B[22,23]. Whether hepatitis B 
virus (HBV) genotypes influence the response to antiviral 
treatment remains controversial. It was reported that HBV 
genotypes do not influence the development of  resistance 
to lamivudine, but influence the severity of  liver disease[24]. 
In the present study, 85.9% of  patients were infected with 
the HBV genotype C and 14.1% with the HBV genotype 
B. There was no significant difference in intrahepatic HBV 
DNA load, serum ALT and HBV DNA level, as well as in 
histological findings before and after treatment between 
the two groups (P > 0.05). After 24 wk of  treatment, both 
sustained virological response rate and ALT normalization 
rate for the two groups were very similar (P > 0.05), 
indicating that HBV genotypes have no influence on 
intrahepatic HBV DNA load. In this study, there was no 
statistically significant difference in the long-term effect of  
antiviral therapy between HBV genotypes B and C.
In conclusion, antiviral therapy can effectively suppress 
intrahepatic HBV DNA replication. Better efficacy of  
antivirus treatment can be achieved in patients with a 
low intrahepatic HBV DNA level. Intrahepatic HBV 
DNA level at the end of  antiviral treatment is correlated 
with the effect of  antiviral therapy, suggesting that loss 
of  intrahepatic HBV DNA may induces less virus flare 
and can be taken as the optimal endpoint of  antiviral 
treatment. There is no significant difference in intrahepatic 
HBV DNA level between HBV genotypes C and B.
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